CYPH

Nov 02, 6:32 PMNo clear catalyst identified as CYPH drops 21% exceeding Zcash and miner peers

Peers: LITS HSDT TONX DFDV SUIG AVAT UPXI TAOX BTCS NA

Index	-
Market Cap	271.56M
Enterprise Value	263.98M
Income	-0.88M
Sales	0.00M
Book/sh	1.29
Cash/sh	0.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	6
IPO	Jan 25, 2017

P/E	4.46
Forward P/E	6.00
PEG	0.04
P/S	-
P/B	1.95
P/C	35.64
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	79.19
Current Ratio	79.19
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	0.57
EPS next Y	0.42
EPS next Q	0.03
EPS this Y	-100.00%
EPS next Y	-
EPS next 5Y	133.40%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	137.89%
Sales Y/Y TTM	-
EPS Q/Q	145.12%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	700.00% -

Insider Own	35.00%
Insider Trans	-0.63%
Inst Own	14.66%
Inst Trans	12.77%
ROA	-1.08%
ROE	-1.21%
ROIC	-0.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.49%
SMA50	-9.36%
SMA200	94.70%
Trades

Shs Outstand	107.76M
Shs Float	70.05M
Short Float	21.07%
Short Ratio	1.15
Short Interest	14.76M
52W High	4.19 -39.86%
52W Low	0.39 541.22%
Volatility	15.87% 13.88%
ATR (14)	0.43
RSI (14)	44.64
Beta	1.11
Rel Volume	0.90
Avg Volume	12.87M
Volume	576,958

Perf Week	-19.62%
Perf Month	-20.50%
Perf Quarter	243.79%
Perf Half Y	135.51%
Perf YTD	117.24%
Perf Year	501.43%
Perf 3Y	39.23%
Perf 5Y	-90.63%
Perf 10Y	-
Recom	1.00
Target Price	4.15
Prev Close	2.36
Price	2.52
Change %	6.78%

Consensus

Strong Buy

Avg. Price Target

$4.15

Implied Upside

+64.7%

Analysts8incl. previous ratings

Rating Distribution5 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 01, 2026	Initiated	CCantor Fitzgerald	Overweight	$0.90	-64.3%
Jan 29, 2025	Downgrade	RRobert W. Baird	Outperform → Neutral	$9 → $1.25	-50.4%
Jan 29, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Jun 28, 2024	Initiated	RRodman & Renshaw	Buy	$8	+217.5%
Oct 04, 2021	Initiated	MMizuho	Buy	$6	+138.1%
Jun 04, 2021	Resumed	RRobert W. Baird	Outperform	$5	+98.4%
Jun 29, 2020	Initiated	PPiper Sandler	Overweight	$6	+138.1%
Feb 11, 2020	Initiated	RRobert W. Baird	Outperform	$6	+138.1%
Nov 15, 2019	Downgrade	RRaymond James	Outperform → Mkt Perform
Sep 13, 2019	Resumed	RRaymond James	Outperform
Mar 07, 2017	Initiated	LLadenburg Thalmann	Buy	$18	+614.3%

Oct-12-26 01:37PM	Winklevoss Twins-Backed Cypherpunk Says Zcash Mining Is 'Nowhere Close' To Bitcoin, AI Sees $10K Potential (Stocktwits)
Oct-07-26 10:01AM	Winklevoss Twins To Launch New Zcash ETF (CryptoProwl) -6.44%
Oct-06-26 02:42PM	Another Zcash ETF Is Coming: Winklevoss Twins File for 'WINK' (decrypt)
12:45PM	Winklevoss Zcash ETF Could Become the Second U.S. Spot ZEC Fund After Grayscales ZCSH (Unchained)
Sep-30-26 09:47AM	Crypto Exchange Gemini Switches Zcash Software (CryptoProwl)
11:23PM	Loading…
Sep-24-26 11:23PM	MRNA On Track To Be September's No. 2 S&P 500 Stock But These 5 Smaller Health Care Names Did Even Better (Stocktwits) +13.02%
Sep-22-26 07:00AM	Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors (PR Newswire) +9.71%
Aug-19-26 05:31AM	Winklevoss-Backed Cypherpunk Launches 'World's Largest' Zcash Mining Fleet (decrypt) +32.85%
Aug-18-26 07:00AM	Cypherpunk Technologies Launches World's Largest Zcash Mining Fleet (PR Newswire) +14.19%
Aug-12-26 07:05AM	Cypherpunk Technologies Reports Second Quarter 2026 Financial Results (PR Newswire)
07:00AM	Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research (PR Newswire)
Jun-05-26 11:49AM	Winklevoss-Backed Zcash Treasury Plunges Nearly 40% on ZEC Privacy Bug Concerns (decrypt) -47.14%
May-14-26 07:05AM	Cypherpunk Technologies Reports First Quarter 2026 Financial Results (PR Newswire) +15.38%
Apr-15-26 12:21PM	Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard (PR Newswire) -5.26%
Mar-16-26 04:50PM	Cypherpunk Reports Full Year 2025 Financial Results (PR Newswire) +21.53% +12.60%
04:19PM	Loading…
Mar-09-26 04:19PM	Zcash Outpaces Bitcoin Gains as Key Development Team Raises $25 Million (decrypt) +5.69%
09:20AM	Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL) (PR Newswire)
Jan-22-26 07:00AM	Cypherpunk Adds Arjun Khemani as Strategic Advisor (PR Newswire)
Jan-21-26 02:42AM	Winklevoss Twins Donate $1.4 Million To Support Zcash Network: 'Privacy Is The Next Frontier In Crypto' (Benzinga)
Dec-31-25 11:57AM	David Beckhams Prenetics Ditches Bitcoin Strategy as Santa Rally Fails (CoinDesk) -11.45%
04:50AM	Winklevoss-backed Cypherpunk buys $28 million of zcash, now owns 1.7% of supply (CoinDesk)
Dec-30-25 06:18PM	Is Zcash the Next Corporate Treasury Play? Cypherpunk Now Holds Nearly 2% (Cryptonews) +11.02%
07:00AM	Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC (PR Newswire)
Dec-19-25 07:00AM	Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor (PR Newswire) +39.02%
Dec-10-25 03:51PM	Surveillance is a "Dangerous Experiment" - Zcash Founder Zooko Wilcox on Why Privacy is Actually the Historical Norm (CoinDesk) -11.11%
06:02AM	Winklevoss Twins Double Down on Zcash Hire ZEC Founder Zooko Wilcox as Advisor (CCN)
Dec-09-25 07:00AM	Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor (PR Newswire) +39.66%
Nov-18-25 07:00AM	Cypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43% (PR Newswire) +22.22%
Nov-14-25 09:55AM	Cypherpunk Stock Soars on Zcash Rebrand. Should You Buy the Crypto Penny Stock Here? (Barchart) +56.25%
Nov-12-25 06:08PM	Winklevoss-backed stock halted multiple times after wild 550% rally (TheStreet) +368.57% -14.15%
05:07PM	Loading…
05:07PM	Leap Therapeutics Surges 300% on $50M Winklevoss-Backed Zcash Bet (CoinDesk)
02:00PM	Billionaire twinsbacked stock surges 100% after buying $50M encrypted Bitcoin (TheStreet)
09:50AM	Leap Therapeutics Rebrands as Cypherpunk Technologies to Focus on Zcash (Coinspeaker)
08:00AM	Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results (PR Newswire)
07:01AM	Zcash Treasury Company Launches With Winklevoss Backing (decrypt)
07:00AM	Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy (PR Newswire)
Oct-20-25 07:00AM	Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 (PR Newswire) -5.24%
Oct-09-25 07:00AM	Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire) -8.55%
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) -17.98%
Oct-06-25 10:54AM	Leap Therapeutics Shares Jump on $59M Winklevoss-Led Crypto Deal (CoinDesk) +43.15%
09:00AM	Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire)
Sep-25-25 07:00AM	Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 (PR Newswire) +12.63%
Aug-14-25 07:00AM	Leap Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) -28.14%
Jun-23-25 07:00AM	Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives (PR Newswire) -18.04%
May-13-25 07:00AM	Leap Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire) +6.64%
Apr-25-25 01:00PM	Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting (PR Newswire)
Apr-15-25 07:00AM	Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer (PR Newswire) +9.77%
Mar-31-25 01:42PM	Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript (Seeking Alpha)
Mar-26-25 01:29PM	Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer (Benzinga) +16.88%
07:05AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
07:00AM	Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study (PR Newswire)
Jan-28-25 07:00AM	Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study (PR Newswire) -71.11%
Jan-06-25 07:00AM	Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-26-24 07:00AM	Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference (PR Newswire) +5.16%
Nov-13-24 07:00AM	Leap Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire) -7.69%
Sep-30-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Aug-12-24 07:00AM	Leap Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
May-13-24 08:31AM	Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress (GuruFocus.com)
07:00AM	Leap Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-29-24 04:01AM	Pipeline Moves: Investigator-led trial of Lillys merestinib in solid tumours terminated (Clinical Trials Arena) -5.54%
Apr-11-24 08:30AM	Leap Therapeutics Announces $40 Million Private Placement (PR Newswire)
Mar-20-24 09:35AM	Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks (Zacks) +15.91%
Mar-18-24 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Jan-16-24 05:05PM	Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-03-24 07:00AM	Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients (PR Newswire) +12.67%
Dec-11-23 04:05PM	Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +11.28%
Nov-21-23 07:00AM	Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +17.87%
Nov-13-23 07:00AM	Leap Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-03-23 09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks) +26.92%
Sep-05-23 07:00AM	Leap Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-14-23 07:00AM	Leap Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Jul-12-23 07:00AM	Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients (PR Newswire) +6.19%
Jun-20-23 12:30PM	Leap Therapeutics Announces Reverse Stock Split (PR Newswire) -23.22%
Jun-04-23 07:11AM	10 Hot Penny Stocks To Buy (Insider Monkey)
May-25-23 05:10PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) -9.82%
May-15-23 07:00AM	Leap Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-26-23 04:05PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) +6.37%
Apr-12-23 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire) +17.67%
Apr-04-23 11:10AM	Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Mar-24-23 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
Mar-17-23 12:26PM	BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate (Benzinga) -16.85%
Mar-16-23 04:05PM	Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 (PR Newswire) +6.05%
Jan-17-23 05:13PM	Leap Therapeutics to acquire Pennsylvania biotech in all-stock deal (American City Business Journals) -14.66%
09:24AM	Leap Therapeutics Shares Fall After Flame Biosciences Acquisition (Benzinga)
08:00AM	Leap Therapeutics Acquires Flame Biosciences (PR Newswire)
Jan-11-23 07:00AM	Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 07:00AM	Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-16-22 05:20AM	Leap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) (Simply Wall St.) -5.12%
Nov-14-22 07:00AM	Leap Therapeutics Reports Third Quarter 2022 Financial Results (PR Newswire) +12.62%
Nov-07-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Oct-26-22 08:19AM	Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-17-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Oct-12-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer (PR Newswire)
Oct-05-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire)
Sep-07-22 07:00AM	Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference (PR Newswire) +8.02%
Sep-06-22 07:00AM	Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors (PR Newswire) +8.72%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oei Khing Djien	Director	Sep 25 '26	Sale	3.92	168,750	661,500	0	Sep 25 06:14 PM
Martin Patricia A.	Director	Sep 23 '26	Sale	3.86	50,000	193,000	118,750	Sep 25 06:13 PM
Dietz Thomas John	Director	Aug 26 '26	Sale	1.72	20,000	34,400	132,500	Aug 27 04:30 PM
Dietz Thomas John	Director	Aug 26 '26	Proposed Sale	1.61	20,000	32,300		Aug 26 11:29 AM
Mirabelli Christopher	Director	Mar 26 '26	Sale	0.71	60,000	42,630	130,376	Mar 30 05:29 PM
CHRISTOPHER MIRABELLI	Director	Mar 26 '26	Proposed Sale	0.71	60,000	42,629		Mar 27 09:35 AM
Mirabelli Christopher	Director	Nov 17 '25	Sale	3.14	676,319	2,123,642	2,136	Nov 19 04:06 PM
CAVANAUGH JAMES H	Director	Nov 17 '25	Sale	3.14	261,840	822,178	0	Nov 19 04:05 PM
ONSI DOUGLAS E	CEO,CFO,Pres.,GC,Treas.&Sec.	Nov 17 '25	Sale	3.14	676,319	2,123,642	2,136	Nov 19 04:05 PM

Cypherpunk Technologies, Inc. engages in providing privacy technology solutions. It manages a digital asset treasury strategy focused on Zcash (ZEC). The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

CFOMr. Douglas E. Onsi J.D.

Chief Investment Officer & DirectorMr. Will McEvoy

Head of MiningKevin Zhang

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cypherpunk Technologies Inc

Upgrade your Finviz experience